These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 1678313

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B, Loor F.
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [Abstract] [Full Text] [Related]

  • 5. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
    Colombo T, Gonzalez Paz O, D'Incalci M.
    Br J Cancer; 1996 Apr; 73(7):866-71. PubMed ID: 8611397
    [Abstract] [Full Text] [Related]

  • 6. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R, Mayer LD.
    Cancer Res; 1997 Dec 01; 57(23):5246-53. PubMed ID: 9393743
    [Abstract] [Full Text] [Related]

  • 7. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.
    Jachez B, Nordmann R, Loor F.
    J Natl Cancer Inst; 1993 Mar 17; 85(6):478-83. PubMed ID: 8095304
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin.
    Krishna R, de Jong G, Mayer LD.
    Anticancer Res; 1997 Mar 17; 17(5A):3329-34. PubMed ID: 9413167
    [Abstract] [Full Text] [Related]

  • 11. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B.
    Leukemia; 1996 Nov 17; 10(11):1741-50. PubMed ID: 8892677
    [Abstract] [Full Text] [Related]

  • 12. [SDZ PSC 833: a novel modulator of MDR].
    Covelli A.
    Tumori; 1997 Nov 17; 83(5 Suppl):S21-4. PubMed ID: 9446255
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM, Goldenberg S, Gottesman MM, Hait WN.
    Cancer Res; 1994 Feb 01; 54(3):730-7. PubMed ID: 7905786
    [Abstract] [Full Text] [Related]

  • 14. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.
    Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F.
    Anticancer Drugs; 1992 Aug 01; 3(4):419-25. PubMed ID: 1421439
    [Abstract] [Full Text] [Related]

  • 15. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
    Naito M, Tsuruo T.
    Cancer Chemother Pharmacol; 1997 Aug 01; 40 Suppl():S20-4. PubMed ID: 9272129
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.
    Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T.
    Acta Oncol; 1995 Aug 01; 34(2):235-41. PubMed ID: 7718262
    [Abstract] [Full Text] [Related]

  • 18. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
    Boesch D, Loor F.
    Anticancer Drugs; 1994 Apr 01; 5(2):229-38. PubMed ID: 7914109
    [Abstract] [Full Text] [Related]

  • 19. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.
    Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, Hiestand PC.
    Int J Cancer; 1992 Feb 20; 50(4):593-7. PubMed ID: 1347037
    [Abstract] [Full Text] [Related]

  • 20. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR, Kelsey SM, Wu YL, Newland AC.
    Br J Haematol; 1995 Jun 20; 90(2):375-83. PubMed ID: 7794760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.